IQVIA Holdings Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IQVIA Holdings Inc.
Biocon chairperson Kiran Mazumdar-Shaw says that venture capital firms have, with their risk-averse approach, "failed" the biotech sector in India. The executive draws attention to how "bold" venture funds that backed mRNA technology a decade ago were reaping gains today.
Cipla moves beyond in-licensing approach and teams up with CDMO Kemwell to develop and progress respiratory biosimilars. Commercialization of products anticipated post 2025.
In this audio interview, the head of IQVIA Biotech (Japan-Asia Pacific) talks to Scrip on a range of aspects around digitalization and virtualization of clinical research in the region, including sharply reduced site contracting timelines. He also touches on the digital product launch efforts that are currently a reality in several markets.
To help reduce medication errors that can harm patients and compromise research results, FDA – pushed by clinical trial sites – looks to exert more control of the labels of investigational drug products.
- Contract Research Organization-CRO
- Other Names / Subsidiaries
- IMS Health, IQVIA Biotech LLC, Novasyte, LLC
- Myriad RBM Inc.